文献速递乳腺癌

早期乳腺癌中基线BMI对多西他赛辅助化疗获益差异的影响

Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.
PubMed 文献 · J Clin Oncol · 2020-07-02

该研究回顾性分析BIG 2-98试验中2887例早期乳腺癌患者,比较含多西他赛与不含多西他赛辅助化疗方案在不同基线BMI下的疗效差异。结果显示,在多西他赛组中,随着BMI升高,DFS和OS降低;而对照组中BMI与生存无关。BMI与ER状态对治疗效果存在联合修饰作用。

要点

  • 多西他赛组中肥胖患者DFS和OS显著低于偏瘦患者。
  • 非多西他赛组中BMI与DFS或OS无差异。
  • BMI与ER状态对多西他赛疗效存在联合修饰作用。

核心结论

  • 在含多西他赛辅助化疗的早期乳腺癌患者中,基线BMI升高与DFS和OS降低相关。
  • 不含多西他赛化疗组中未观察到BMI与DFS或OS的关联。
  • BMI与ER状态对多西他赛治疗效应存在联合修饰作用。

研究设计与样本

  • 回顾性分析BIG 2-98试验(NCT00174655)全部2887例早期乳腺癌患者。
  • 比较不含多西他赛与含多西他赛的辅助化疗方案。
  • BMI分类:18.5至<25为偏瘦,25至<30为超重,≥30为肥胖。
  • 主要终点为无病生存期(DFS),次要终点为总生存期(OS)。

主要发现

  • 非多西他赛组中,按BMI分类的DFS或OS无差异。
  • 分别考虑ER阴性或ER阳性肿瘤,或仅纳入多西他赛相对剂量强度≥85%的患者时,结果相似。

临床怎么用

  • 对于早期乳腺癌患者,选择含多西他赛辅助化疗时需考虑基线BMI对疗效的影响。
  • 肥胖患者接受多西他赛辅助化疗可能获益降低,需基于体成分重新评估风险获益比。

局限性

  • 为回顾性分析,结果需在额外系列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lipophilic drugs, such as taxanes, have a high affinity for adipose tissue and a resulting higher volume of distribution. Here, we reanalyzed clinical trial data to investigate whether the efficacy of docetaxel-based chemotherapy differs from non-docetaxel-based chemotherapy in patients with breast cancer according to their baseline body mass index (BMI). PATIENTS AND METHODS: We retrospectively analyzed data from all of the patients in the adjuvant BIG 2-98 trial (ClinicalTrials.gov identifier: NCT00174655; N = 2,887) comparing non-docetaxel- to docetaxel-containing chemotherapy. BMI (kg/m2) was categorized as follows: 18.5 to < 25, lean; 25 to < 30, overweight; and ≥ 30, obese. Disease-free survival (DFS) was the primary endpoint, and overall survival (OS) was the secondary endpoint. A second-order interaction was assessed among treatment, BMI, and estrogen receptor (ER) status. RESULTS: There was no difference in DFS or OS according to BMI in the non-docetaxel group, while reduced DFS and OS were observed with increasing BMI category in the docetaxel group. Adjusted hazard ratios for DFS and OS were, respectively, 1.12 (95% CI, 0.98 to 1.50; P = .21) and 1.27 (95% CI, 1.01 to 1.60; P = .04) for overweight versus lean groups and were 1.32 (95% CI, 1.08 to 1.62; P = .007) and 1.63 (95% CI, 1.27 to 2.09; P < .001), respectively, for obese versus lean groups. Similar results were obtained when considering ER-negative and ER-positive tumors separately and when considering only patients who received a relative dose intensity ≥ 85% for docetaxel. A joint modifying role of BMI and ER status on treatment effect was evident for DFS (adjusted P = .06) and OS (adjusted P = .04). CONCLUSION: This retrospective analysis of a large adjuvant trial highlights a differential response to docetaxel according to BMI, which calls for a body composition-based re-evaluation of the risk-benefit ratio of the use of taxanes in breast cancer. These results now must be confirmed in additional series.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Desmedt C, Fornili M, Clatot F, et al. Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index. J Clin Oncol. 2020. PMID: 32614702. doi:10.1200/JCO.19.01771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。